UBS analyst Peter Lennox-King believes this new source of money for GE, as well as the benefits, is a blessing to the company.
"The sale of GE BioPharma to Danaher effectively puts the issue at bay," Lennox-King said.
Nicole DeBlase, analyst from Deutsche Bank, was anyway among the groups, but despite raising the firm's price target for GE to $ 11 per share.
"GE is left with the less attractive parts of the Healthcare business," said DeBlase of the deal.
Here's what great Wall Street analysts said about GE's deal.